Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis

Matthew Spite, Lucy V. Norling, Lisa Summers, Rong Yang, Dianne Cooper, Nicos A. Petasis, Roderick J. Flower, Mauro Perretti and Charles N. Serhan ()
Additional contact information
Matthew Spite: Center for Experimental Therapeutics and Reperfusion Injury, Perioperative and Pain Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
Lucy V. Norling: Center for Experimental Therapeutics and Reperfusion Injury, Perioperative and Pain Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
Lisa Summers: Center for Experimental Therapeutics and Reperfusion Injury, Perioperative and Pain Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
Rong Yang: Center for Experimental Therapeutics and Reperfusion Injury, Perioperative and Pain Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
Dianne Cooper: William Harvey Research Institute, Barts and the London Medical School, Queen Mary University of London
Nicos A. Petasis: University of Southern California, Los Angeles, California 90089, USA
Roderick J. Flower: William Harvey Research Institute, Barts and the London Medical School, Queen Mary University of London
Mauro Perretti: William Harvey Research Institute, Barts and the London Medical School, Queen Mary University of London
Charles N. Serhan: Center for Experimental Therapeutics and Reperfusion Injury, Perioperative and Pain Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA

Nature, 2009, vol. 461, issue 7268, 1287-1291

Abstract: Anti-inflammatory activity of resolvin D2 Resolvins, locally acting factors derived from omega-3 fatty acids, have been recognized as inflammation-resolving mediators. Experiments in a mouse abdominal sepsis model now show that resolvin D2 (RvD2) inhibits neutrophil trafficking to inflammatory sites and decreases leukocyte interactions with endothelial cells in a nitric oxide-dependent manner. RvD2's cellular and molecular actions translated to a dramatic increased survival. This work points to RvD2 as a potent anti-inflammatory agent and suggests new therapeutic approaches that do not compromise host defences.

Date: 2009
References: Add references at CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
https://www.nature.com/articles/nature08541 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:461:y:2009:i:7268:d:10.1038_nature08541

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature08541

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().